Unum Therapeutics Inc. (UMRX)
(Delayed Data from NSDQ)
$3.35 USD
+0.07 (2.13%)
Updated May 3, 2019 04:13 PM ET
After-Market: $3.32 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.35 USD
+0.07 (2.13%)
Updated May 3, 2019 04:13 PM ET
After-Market: $3.32 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Unum Therapeutics Inc. (UMRX) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Unum Therapeutics Inc. (UMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Unum Therapeutics Inc. (UMRX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Unum Therapeutics Inc. (UMRX) delivered earnings and revenue surprises of 12.82% and 1.36%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Amicus (FOLD) Q2 Earnings Match, Stock Falls on Weak Q3 View
by Zacks Equity Research
Amicus' (FOLD) earnings meet estimates in the second quarter while revenues beat the same.
Unum Therapeutics' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Unum Therapeutics.
Unum Therapeutics Inc. (UMRX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Unum Therapeutics Inc. (UMRX) delivered earnings and revenue surprises of -25.81% and -2.96%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Life Sciences Sales Boost Bio-Rad's (BIO) Q1 Earnings?
by Zacks Equity Research
Within the Life Sciences segment, high investment in several geographies along with product launches and new technologies is resulting in a strong upside for Bio-Rad (BIO).
Unum Therapeutics Inc. (UMRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Unum Therapeutics Inc. (UMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Epidolex Drive GW Pharmaceuticals' (GWPH) Q2 Earnings?
by Zacks Equity Research
Following the U.S.-commercial launch of Epidolex last November, GW Pharmaceuticals (GWPH) continues to see an uptick from the same.